Abstract: Embodiments of the present invention are directed to processes for the production of (R)-3-hydroxybutyl (R)-3-hydroxybyrate. Poly (R)-3-hydroxybyrate is transesterified with an alcohol, to form a first ester portion and a second ester portion. The first ester portion is reduced to the diol to form a diol portion and the diol portion is reacted with the second ester portion to produce (R)-3-hydroxybutyl (R)-3-hydroxybyrate.

Abstract: The present invention relates to a resist composition, especially for use in the production of electronic components via electron beam lithography. In addition to the usual base polymeric component (resist polymer), a secondary electron generator is included in resist compositions of the invention in order to promote secondary electron generation. This unique combination of components increases the exposure sensitivity of resists in a controlled fashion which facilitates the effective production of high-resolution patterned substrates (and consequential electronic components), but at much higher write speeds.

Abstract: Disclosed is a system with (a) a microplate comprising a metallic material for heating one or more samples during thermocycling. The microplate comprises one or more barcodes on a side of the microplate. The system may comprise a barcode reader for reading the one or more barcode. The system may also comprise a first temperature block configured to receive the microplate and/ or provide a denaturing temperature to the one or more samples contained in the microplate, during the thermocycling. The system may also comprise a second temperature block configured to receive the microplate and/or provide an extension temperature to the one or more samples contained in the microplate, during the thermocycling. The system may also comprise a conveyor configured to move the microplate between a sensing device, the first temperature block, and the second temperature block, during the thermocycling.

Abstract: Expanded graphite and/or vermiculite are introduced into the friction lining mixture to eliminate or substantially reduce the amount of binder present therein. The friction lining at most contains from 2.5% by weight of binder. By omitting/reducing binder, the production is very stable and the friction linings can be easily reproduced. The process steps of hardening (including the hardening furnace) and scorching (including the necessary equipment) can be omitted when making such friction linings.

Abstract: A nozzle tip for a pulverized solid fuel pipe nozzle of a pulverized solid fuel-fired furnace is provided. The nozzle tip includes an inner nozzle portion and an outer nozzle portion that receives therein the inner nozzle portion. The outer nozzle portion has a lower supporting surface that is configured to support a lower surface of the inner nozzle portion. The outer nozzle portion also includes a plurality of ribs that define therebetween a plurality of flow passages for the passage of air. The ribs, in addition to define the airflow passages, provide bolstering support for the lower supporting surface. The outer nozzle portion is formed from stainless steel.

Abstract: A direct conversion x-ray detection apparatus having a planar x-ray detection layer having a detection layer upper surface and a detection layer lower surface, the planar x-ray detection layer including a lead halide perovskite material; a top electrode layer above the detection layer upper surface; a bottom electrode layer below the detection layer lower surface and in conductive communication with the top electrode layer through the x-ray detection layer to apply a bias voltage across the x-ray detection layer; and a blocking layer between the x-ray detection layer and the top electrode layer to inhibit a dark current, the blocking layer including a polymer selected from the group comprising polyacrylates, polyimides, polyamides, polysulfones, polystyrenes, and polycarbonates.

Abstract: Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic ?-hydroxybutyrate or D-?-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic ?-hydroxybutyrate or D-?-hydroxybutyrate, esters of D-?-hydroxybutyrate, oligomers of D-?-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject.

Abstract: The invention is a cap for a pathogen sample tube, the tube having an open end and the cap being configured to secure the open end of the tube to prevent spillage of any sample stored in the tube. The cap includes a first pierceable protective film section configured to enable an automated pipette or other sample withdrawal system to pierce the protective film section and to aspirate at least some of the sample. The cap also includes a second pierceable protective film section lying underneath the first pierceable protective film section; the film sections are separated by an air gap, that is approximately 2 mm in depth. The film sections are made from a thin aluminium foil that is approximately 25 microns thick, with a thin lacquer coating on its upper side and a co-extrusion coating, such as a polymer coating, on the lower side.

Abstract: Embodiments of the present invention are directed to processes for the production of (R)-3-hydroxybutyl (R)-3-hydroxybyrate. Poly (R)-3-hydroxybyrate is transesterified with an alcohol, to form a first ester portion and a second ester portion. The first ester portion is reduced to the diol to form a diol portion and the diol portion is reacted with the second ester portion to produce (R)-3-hydroxybutyl (R)-3-hydroxybyrate.

Abstract: Embodiments herein describe a multi-port memory system that includes one or more single port memories (e.g., a memory that can perform only one read or one write at any given time, referred to as a 1W or 1R memory). That is, the multi-port memory system can perform multiple read and writes in parallel (e.g., 1R/1W, 1R/3W, 2R/2W, 3R/1W, etc.) even though the memory in the system can only perform one read or one write at any given time. The advantage of doing so is a reduction in area and power.

Abstract: A method of treating obstructive sleep apnea according to this disclosure may include: providing an implant comprising a substantially planar central body portion having a top side and a bottom side; at least two adjustable wing portions; and at least two connecting members, each one of the at least two connecting members extending from opposite sides of the central body portion, the each one of the at least two connecting members being configured for flexibly connecting each one of the at least two wing portions at opposite sides to said central body portion; forming a surgical opening to expose a genioglossus muscle; exposing a branch of a hypoglossal nerve for stimulation by the implant at least on one side of the geniouglossus; forming at least one pocket on at least one side of the geniouglossus; such that the pocket dimensions are configured to fit the at least one of the at least two wing portions of the device; inserting an implant device through the surgical opening such that the central body extends

Abstract: Glaucoma can be treated by implanting an intraocular shunt in the eye. The implantation can be performed by first determining an entry area below a corneal limbus of an eye. Thereafter, the intraocular shunt can be inserted into eye tissue through the entry area such that an inflow end of the shunt is positioned in the anterior chamber of the eye and an outflow end of the shunt is positioned between layers of Tenon's capsule.

Abstract: Glaucoma can be treated by implanting an intraocular shunt into an eye. The eye has an anterior chamber and sclera. A shunt can be placed into the eye to establish fluid communication from the anterior chamber of the eye through the sclera, and a pharmaceutical or biological agent can be administered to the eye.

Abstract: Disclosed herein are compounds of structural Formula VIIa or VIIb: or a pharmaceutically acceptable salt thereof, and compositions thereof useful in the treatment of GLS1 mediated diseases, such as cancer. Methods of inhibition GLS1 activity in a human or animal subject are also provided.

Abstract: Embodiments herein describe a multi-port memory system that includes one or more single port memories (e.g., a memory that can perform only one read or one write at any given time, referred to as a 1W or 1R memory). That is, the multi-port memory system can perform multiple read and writes in parallel (e.g., 1R/1W, 1R/3W, 2R/2W, 3R/1W, etc.) even though the memory in the system can only perform one read or one write at any given time. The advantage of doing so is a reduction in area and power.

Abstract: An electrical connector includes a coupling nut configured to at least partially surround a connector body. The coupling nut includes a first end and a second opposing end. The first end is configured to interface with a mating connector. The coupling nut further includes an inner thread portion located between the first and second ends; and a sealing member located at the first end. The sealing member has a base and a deformable wiper portion. The sealing member is configured to flex between deformed and non-deformed states when coupling the coupling nut to the mating connector. The base of the sealing member is in contact with an inner surface of the first end and the deformable wiper portion extends radially inwardly from the base.

Abstract: Novel compounds and compositions containing (R)-3-hydroxybutyrate derivatives are disclosed. The compounds and compositions can be used as nutritional supplements to increase physical performance and as therapeutics to ameliorate symptoms of medical conditions, particularly neurological conditions, such as Alzheimer's and similar conditions. Novel methods for making R-3-hydroxybutyrate derivatives also are disclosed. Exemplary methods employ a supercritical solvent, such as supercritical carbon dioxide, and employ a lipase catalyzed esterification or transesterification reaction to produce the (R)-3-hydroxybutyrate derivatives.